"BMS" の関連情報検索結果

The Bristol Myers Squibb Foundation - Bristol Myers Squibb



The Bristol Myers Squibb Foundation  Bristol Myers Squibb

BMS secures subcutaneous Opdivo approval - FirstWord Pharma



BMS secures subcutaneous Opdivo approval  FirstWord Pharma

FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo - Reuters



FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo  Reuters

LGES, Qualcomm to collaborate on chip-based BMS - evertiq.com



LGES, Qualcomm to collaborate on chip-based BMS  evertiq.com

Our impact - Bristol Myers Squibb



Our impact  Bristol Myers Squibb

About us - Bristol Myers Squibb



About us  Bristol Myers Squibb

With pair of trial wins in psoriatic arthritis, Bristol Myers Squibb looks to jump-start stagnant...



With pair of trial wins in psoriatic arthritis, Bristol Myers Squibb looks to jump-start stagnant Sotyktu  FiercePharma

Global Inclusion & Diversity - Bristol Myers Squibb



Global Inclusion & Diversity  Bristol Myers Squibb

Working at BMS - Bristol Myers Squibb



Working at BMS  Bristol Myers Squibb

Our company: Industry leadership in BioPharma - Bristol Myers Squibb



Our company: Industry leadership in BioPharma  Bristol Myers Squibb

BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects - Fierce Biotech



BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects  Fierce Biotech

Families flock to BMS for yearly ice rink activities - WJHL-TV News Channel 11



Families flock to BMS for yearly ice rink activities  WJHL-TV News Channel 11

Pharmaceutical business development - Bristol Myers Squibb



Pharmaceutical business development  Bristol Myers Squibb

BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Centu...



BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Century, Immatics  Fierce Biotech

Positive Phase III trials results with BMS’ Sotyktu - The Pharma Letter



Positive Phase III trials results with BMS’ Sotyktu  The Pharma Letter

Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M - Fierce ...



Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M  Fierce Biotech

Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls o...



Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls on  FiercePharma

Bristol Myers Squibb latest drug company to sue HHS over 340B rebate model - Fierce healthcare



Bristol Myers Squibb latest drug company to sue HHS over 340B rebate model  Fierce healthcare

Psoriasis around the world - Bristol Myers Squibb



Psoriasis around the world  Bristol Myers Squibb

Areas of interest - Bristol Myers Squibb



Areas of interest  Bristol Myers Squibb

Patients and caregivers - Bristol Myers Squibb



Patients and caregivers  Bristol Myers Squibb

Our technologies - Bristol Myers Squibb



Our technologies  Bristol Myers Squibb

BMS sees success in Phase III Sotyktu psoriatic arthritis trials - Yahoo Finance



BMS sees success in Phase III Sotyktu psoriatic arthritis trials  Yahoo Finance

Michael R. McMullen - Bristol Myers Squibb



Michael R. McMullen  Bristol Myers Squibb

People and business resource groups - Bristol Myers Squibb



People and business resource groups  Bristol Myers Squibb

Independent research - Bristol Myers Squibb



Independent research  Bristol Myers Squibb

Clinical trials & studies - Bristol Myers Squibb



Clinical trials & studies  Bristol Myers Squibb

Global Inclusion & Diversity Report - Bristol Myers Squibb



Global Inclusion & Diversity Report  Bristol Myers Squibb

Advancing Lymphoma Treatment with Protein Degradation - Bristol Myers Squibb



Advancing Lymphoma Treatment with Protein Degradation  Bristol Myers Squibb

Get help paying for your medicines - Bristol Myers Squibb



Get help paying for your medicines  Bristol Myers Squibb

Our research in immunology - Bristol Myers Squibb



Our research in immunology  Bristol Myers Squibb

Post study drug access to BMS investigational medicinal products and approved products - Bristol ...



Post study drug access to BMS investigational medicinal products and approved products  Bristol Myers Squibb

Become a business supplier - Bristol Myers Squibb



Become a business supplier  Bristol Myers Squibb

BMS’ Cobenfy tipped to be top dog in growing schizophrenia space - FiercePharma



BMS’ Cobenfy tipped to be top dog in growing schizophrenia space  FiercePharma

BMS stakes new ground for Sotyktu with Phase III wins in psoriatic arthritis - FirstWord Pharma



BMS stakes new ground for Sotyktu with Phase III wins in psoriatic arthritis  FirstWord Pharma

Pre-approval access to investigational medicines - Bristol Myers Squibb



Pre-approval access to investigational medicines  Bristol Myers Squibb

Transparency & reporting - Bristol Myers Squibb



Transparency & reporting  Bristol Myers Squibb

Breaking barriers: SOGIIS data collection for improved health equity in clinical trials - Bristol...



Breaking barriers: SOGIIS data collection for improved health equity in clinical trials  Bristol Myers Squibb

Immunology patient resources - Bristol Myers Squibb



Immunology patient resources  Bristol Myers Squibb

BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal - BioSpace



BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal  BioSpace

Worldwide locations - Bristol Myers Squibb



Worldwide locations  Bristol Myers Squibb

Professional Service Automation Software for IT Professionals | Kaseya BMS - Kaseya



Professional Service Automation Software for IT Professionals | Kaseya BMS  Kaseya

Global Patient Week 2024 - Bristol Myers Squibb



Global Patient Week 2024  Bristol Myers Squibb

BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma - OncLive



BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma  OncLive

Our research in neuroscience - Bristol Myers Squibb



Our research in neuroscience  Bristol Myers Squibb

Position biopharma industry key issues - Bristol Myers Squibb



Position biopharma industry key issues  Bristol Myers Squibb

Our science - Bristol Myers Squibb



Our science  Bristol Myers Squibb

Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC - OncLive



Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC  OncLive

Highlights from our 2024 Climate Change Report - Bristol Myers Squibb



Highlights from our 2024 Climate Change Report  Bristol Myers Squibb

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluatin...



Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis  Business Wire

Early innovation at BMS - Bristol Myers Squibb



Early innovation at BMS  Bristol Myers Squibb

Translational medicine - Bristol Myers Squibb



Translational medicine  Bristol Myers Squibb

Science Firsthand: The pathway to drug discovery - Bristol Myers Squibb



Science Firsthand: The pathway to drug discovery  Bristol Myers Squibb

BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1 - Fierce Biotech



BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1  Fierce Biotech

Research and development areas of focus - Bristol Myers Squibb



Research and development areas of focus  Bristol Myers Squibb

Science Firsthand: Translating the promise of cell therapy - Bristol Myers Squibb



Science Firsthand: Translating the promise of cell therapy  Bristol Myers Squibb

Survivorship Today: Cancer survivor stories - Bristol Myers Squibb



Survivorship Today: Cancer survivor stories  Bristol Myers Squibb

LGES launches its own battery management solution - www.electrive.com



LGES launches its own battery management solution  www.electrive.com

Leveraging AI to enhance workplace innovation & efficiency - Bristol Myers Squibb



Leveraging AI to enhance workplace innovation & efficiency  Bristol Myers Squibb

LG Energy Solution Announces Availability of Advanced Battery Management System Solutions for Aut...



LG Energy Solution Announces Availability of Advanced Battery Management System Solutions for Automotive  Batteries News

Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace



Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments  BioSpace

Our commitment towards transforming multiple myeloma treatment - Bristol Myers Squibb



Our commitment towards transforming multiple myeloma treatment  Bristol Myers Squibb

A new era in Alzheimer's R&D: Dual approach to disease modification and symptom management - Bris...



A new era in Alzheimer's R&D: Dual approach to disease modification and symptom management  Bristol Myers Squibb

ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Dir...



ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with mCRPC  UroToday

Advancing one’s growth and career development through a culture of inclusion and belonging - Bris...



Advancing one’s growth and career development through a culture of inclusion and belonging  Bristol Myers Squibb

BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years - BioSpace



BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years  BioSpace

Celebrating four years of patient engagement through PEER program - Bristol Myers Squibb



Celebrating four years of patient engagement through PEER program  Bristol Myers Squibb

ASPIRE: Our commitment to address health inequities in low- and middle-income countries - Bristol...



ASPIRE: Our commitment to address health inequities in low- and middle-income countries  Bristol Myers Squibb

BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipelin...



BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline  Fierce Biotech

Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS) - Bristol Mye...



Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS)  Bristol Myers Squibb

The evolution of lung cancer research - Bristol Myers Squibb



The evolution of lung cancer research  Bristol Myers Squibb

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Th...



U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma  Bristol Myers Squibb - News

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $...



Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research  Bristol Myers Squibb - News

Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking ...



Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking it?  Bristol Myers Squibb

Continuing Innovations on TYK2 Inhibition - Bristol Myers Squibb



Continuing Innovations on TYK2 Inhibition  Bristol Myers Squibb

Reigniting Innovation in Neuropsychiatry - Bristol Myers Squibb



Reigniting Innovation in Neuropsychiatry  Bristol Myers Squibb

How BMS employees champion STEM education & diversity - Bristol Myers Squibb



How BMS employees champion STEM education & diversity  Bristol Myers Squibb

Developing tools to break the rules: Fostering innovation in cell therapy manufacturing - Bristol...



Developing tools to break the rules: Fostering innovation in cell therapy manufacturing  Bristol Myers Squibb

BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study - BioSpace



BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study  BioSpace

Driving innovative and inclusive practices at all levels of the BMS organization - Bristol Myers ...



Driving innovative and inclusive practices at all levels of the BMS organization  Bristol Myers Squibb

Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends - BioSpace



Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends  BioSpace

Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research - Bristol Myers Squibb



Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research  Bristol Myers Squibb

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administrat...



Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma  Bristol Myers Squibb - News

The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia - BioSpace



The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia  BioSpace

ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer fiel...



ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field  FiercePharma

BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific - Fierce Biotech



BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific  Fierce Biotech

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapse...



U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy  Bristol Myers Squibb - News

Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline - BioSpace



Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline  BioSpace

2024 Annual Meeting of Shareholders - Bristol Myers Squibb



2024 Annual Meeting of Shareholders  Bristol Myers Squibb

As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency' - ...



As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency'  FiercePharma

Unusual Liposome Image During Drug Research and Development - Bristol Myers Squibb



Unusual Liposome Image During Drug Research and Development  Bristol Myers Squibb

BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody - BioSpace



BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody  BioSpace

insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement ...



insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS  BioSpace

Bringing the science of cell therapy into autoimmune diseases - Bristol Myers Squibb



Bringing the science of cell therapy into autoimmune diseases  Bristol Myers Squibb

Compañía Biofarmacéutica Global - Bristol Myers Squibb



Compañía Biofarmacéutica Global  Bristol Myers Squibb

Chris Boerner, PhD - Bristol Myers Squibb



Chris Boerner, PhD  Bristol Myers Squibb

Former BMS Professor and GeniPhys Founder Sees Continued Success in Development of Wound Manageme...



Former BMS Professor and GeniPhys Founder Sees Continued Success in Development of Wound Management Product  Purdue University

Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on - Fierce...



Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on  FiercePharma

Spreading eosinophilic esophagitis awareness and wellness in patients - Bristol Myers Squibb



Spreading eosinophilic esophagitis awareness and wellness in patients  Bristol Myers Squibb

Annual reports - Bristol Myers Squibb



Annual reports  Bristol Myers Squibb